Stopping Nerve Tumors in NF1 Patients
TAM receptor inhibition in NF1-associated peripheral nerve sheath tumors
This research explores new ways to stop nerve tumors from growing and becoming cancerous in people with Neurofibromatosis type 1 (NF1).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11101324 on NIH RePORTER |
What this research studies
Neurofibromatosis type 1 (NF1) is a genetic condition that often leads to nerve tumors called plexiform neurofibromas, which can sometimes turn into a very aggressive cancer. This project uses advanced mouse models that closely mimic how these tumors develop and progress in humans. Researchers have identified specific targets, called TAM family kinases, that play a key role in these tumors. They are exploring a drug called cabozantinib, which blocks these targets, and has shown promise in delaying or preventing tumor progression in these models, with some early clinical observations also supporting this approach. The goal is to understand how this drug works to prevent these tumors from becoming cancerous.
Who could benefit from this research
Good fit: Patients with Neurofibromatosis type 1 (NF1) who have plexiform neurofibromas or atypical neurofibromas that are at risk of becoming cancerous are the focus of this research.
Not a fit: Patients without NF1 or those whose tumors have already progressed to advanced, aggressive forms might not directly benefit from this specific preventative approach.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or significantly delay the progression of NF1-related nerve tumors into life-threatening cancers.
How similar studies have performed: Preliminary clinical data and preclinical models suggest this approach has shown some promise in delaying tumor progression.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Clapp, David W — Indiana University Indianapolis
- Study coordinator: Clapp, David W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.